Elsevier

Medical Hypotheses

Volume 115, June 2018, Pages 54-57
Medical Hypotheses

The potential for evaluating the effects of intensified antithrombotic therapy using retinal optical coherence tomography angiography

https://doi.org/10.1016/j.mehy.2018.03.022Get rights and content

Abstract

Oral anticoagulants are widely used in the treatment and prevention of both venous and arterial thromboembolism. They are classified into vitamin K anticoagulants (VKAs) and non-vitamin K antagonist oral anticoagulants (NOACs). The main advantage of NOACs over VKAs is the absence of the need for continuous monitoring. However, there are concerns about their effectiveness and safety in certain clinical situations. In this manuscript, I discussed the possibility of using optical coherence tomography angiography [OCTA] in the monitoring of the activity of NOACs. The rapid development of OCTA technology is very promising. Further research and development will extend its use beyond the realm of ophthalmology.

Section snippets

Background

Oral anticoagulants are widely used in the treatment and prevention of both venous and arterial thromboembolism. They are classified into vitamin K anticoagulants (VKAs) and non-vitamin K antagonist oral anticoagulants (NOACs). Warfarin was approved by the United States Food and Drug Administration [US FDA] in 1954 [1]. It acts by inhibiting the synthesis of vitamin K-dependent clotting factors [Factors II, VII, IX, and X] via inhibition of the C1 subunit of vitamin K epoxide reductase [VKORC1]

Monitoring of oral anticoagulants

The main advantage of NOACs over VKAs is the absence of the need for continuous monitoring. For warfarin, there is a need to maintain the patient within a therapeutic window by dose adjustment. NOACs have wide therapeutic window due to their predictable pharmacokinetics and pharmacodynamics, a rapid onset and offset of action, and a short half-life.

Currently, there are few haematological methods to monitor the activity of oral anticoagulants. Activated partial thromboplastin time [aPTT] and

Optical coherence tomography [OCT] and optical coherence tomography angiography [OCTA]

The use of OCT for the human eye was first presented at the International Conference of Optics in Life Sciences in 1990 [8]. Since then, the technology has evolved tremendously. The current OCT machines are able to provide resolution details of retinal images in the order of few micrometers.

OCTA is a non-invasive imaging technique that provides angiographic information of the retinal blood vessels. Gao et al. and de Carlo et al. have discussed extensively on the history and principles of OCTA

Case study

A 75 year old gentleman with chronic atrial fibrillation was on maintenance therapy apixaban 5 mg twice daily. He was admitted for left acute brachial artery thrombosis. The condition was successfully treated with intravenous alteplase, which was then continued with subcutaneous enoxaparin 50 mg twice daily. While on the above treatment, he experienced amaurosis fugax. Retinal emboli were detected (Fig. 1). OCTA showed a poorly defined parafoveal capillary network (Fig. 2). The patient was

Discussion

Routine coagulation profile [PT/INR/aPPT] was performed but was of limited use as the patient was treated with NOACs and anti-platelet therapy. In this particular situation, OCTA provided a very useful guide to the clinicians as to adjustment of the dosage of these medications. A well-defined parafoveal capillary network (Fig. 4) after treatment can be translated clinically into a significant improvement of retinal blood flow and more importantly therapeutic efficacy.

The quantification of flow

Future research

Further studies using double-blinded randomised controlled trials are needed to confirm the above observation. Besides vessel density and flow index, researchers should develop new or novel parameters to measure the effects of anticoagulants on the parafoveal capillary network.

Conclusion

Retinal OCTA has great potential. Further research and development will extend its use beyond the realm of ophthalmology.

Conflict of interest statement

The author declared that he has no competing interests.

References (10)

  • K. Ikeda et al.

    Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation

    J Arrhythmia

    (2016)
  • Y.H. Mekaj et al.

    New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

    Therap Clin Risk Manage

    (2015)
  • L. Hayes et al.

    Dabigatran [Praxada] monitoring and reversal

    Melbourne Pathol

    (2011)
  • M.I. Samoš et al.

    Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation

    J Thromb Thrombol

    (2015)
  • A. Cuker et al.

    Laboratory measurement of the anticoagulant activity of edoxa-ban: a systematic review

    J Thromb Thrombolysis

    (2015)
There are more references available in the full text version of this article.

Cited by (0)

View full text